Q1 Earnings Estimate for Soligenix Issued By Zacks Small Cap

Soligenix, Inc. (NASDAQ:SNGX) – Equities researchers at Zacks Small Cap issued their Q1 2025 earnings per share estimates for Soligenix in a research report issued on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz anticipates that the biopharmaceutical company will earn ($0.67) per share for the quarter. The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.79) EPS and FY2027 earnings at ($1.75) EPS.

Soligenix Trading Down 2.6 %

Shares of Soligenix stock opened at $2.21 on Thursday. The stock has a market capitalization of $5.55 million, a price-to-earnings ratio of -0.29 and a beta of 2.03. The firm’s 50-day moving average price is $2.34 and its two-hundred day moving average price is $3.07. Soligenix has a 1-year low of $1.83 and a 1-year high of $14.92.

Soligenix (NASDAQ:SNGX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. During the same period in the previous year, the company posted ($12.66) EPS.

Institutional Investors Weigh In On Soligenix

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC grew its holdings in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,094 shares of the biopharmaceutical company’s stock after purchasing an additional 7,729 shares during the quarter. Geode Capital Management LLC owned about 1.04% of Soligenix worth $71,000 as of its most recent filing with the SEC. 3.60% of the stock is owned by hedge funds and other institutional investors.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.